HER2 Inhibitor Approved for Certain Newly Diagnosed, HER2-mutant Lung Cancers
Sevabertinib received accelerated approval as first-line treatment for some lung cancers with HER2 activating mutations. The U.S. Food and...
Progress Against Cancer
Sevabertinib received accelerated approval as first-line treatment for some lung cancers with HER2 activating mutations. The U.S. Food and...
Ropeginterferon alfa-2b-njft treats essential thrombocythemia by targeting blood-forming cells in the bone marrow. The U.S. Food and Drug Administration...
Therapy helps control excessive red blood cell production. The U.S. Food and Drug Administration (FDA) has approved rusfertide (Mimrylo)...
Two zanidatamab-based regimens were approved for certain HER2-positive advanced gastric, gastroesophageal junction, or esophageal cancers. The U.S. Food and...
The new agent was approved in combination with daratumumab and hyaluronidase-fihj and dexamethasone for patients with resistant or refractory...
Vusolimogene oderparepvec-wtpg and nivolumab earned accelerated approval to treat patients with advanced melanoma after PD-1 therapy. The U.S. Food...
Lutetium Lu 177 vipivotide tetraxetan is the first radioligand therapy approved for metastatic prostate cancer that responds to hormone...
Zidesamtinib, a next-generation ROS1 inhibitor, was approved for ROS1-positive NSCLC previously treated with ROS1 inhibition. The U.S. Food and...
Gedatolisib received its first FDA approval for advanced HR-positive, HER2-negative breast cancer without mutations in PIK3CA. The U.S. Food...
The RET inhibitor received traditional approval to treat RET-fusion-positive solid tumors. The U.S. Food and Drug Administration (FDA) has...